中国肿瘤生物治疗杂志2024，Vol.31Issue(1)：54-61,8.DOI:10.3872/j.issn.1007-385x.2024.01.008
非小细胞肺癌患者免疫检查点抑制剂相关性肺炎与免疫检查点抑制剂疗效相关性分析
Analysis of the relationship between checkpoint inhibitor-related pneumonitis and the efficacy of immune checkpoint inhibitor in patients with non-small cell lung cancer
摘要
Abstract
Objective:To investigate the relationship between the incidence of immune checkpoint inhibitor-associated pneumonia(CIP)and the efficacy of immunotherapy in non-small cell lung cancer(NSCLC)patients treated with immune checkpoint inhibitors(ICIs),and to explore the prognostic factors of patients receiving ICI treatment.Methods:The clinical and follow-up data of 145 NSCLC patients treated with ICIs in the Affiliated Cancer Hospital of Xinjiang Medical University from March 2020 to March 2023 were retrospectively analyzed.The patients were divided into CIP group and non-CIP group.The patients with CIP were sub-divided into mild(grade 1,2)and severe(grade 3,4)CIP subgroups.The effects of the occurrence and severity of CIP on the overall survival(OS)time and progression-free survival(PFS)time of the patients were analyzed by comparing the survival curve using Kaplan-Meier method.Univariate and multivariate COX proportional hazard regression models were used to analyze the prognostic factors associated with PFS and OS.Results:A total of 26 patients developed CIP,with an incidence rate of 17.93%(26/145),and the incidence of severe CIP was 3.4%.The PFS in CIP group was significantly longer than that in non-CIP group(12.3 vs 7.6 months,P<0.05).There was no significant difference in OS between CIP group and non-CIP group(16.2 vs 15.8 months,P>0.05).Subgroup analysis showed that there were no significant differences in PFS(12.2 vs 12.9 months)and OS(16.1 vs 17.8 months)between mild CIP and severe CIP groups(all P>0.05).Multivariate COX regression analysis showed that CIP(HR=0.55,95%CI[0.33,0.90],P=0.02)and the course of immunotherapy>6 cycles(HR=0.51,95%CI[0.31,0.85],P=0.01)were favorable prognostic factors for PFS.The course of immunotherapy>6 cycles(HR=0.4,95%CI[0.18,0.88],P=0.02)was a favorable prognostic factor for OS.Conclusion:The incidence of CIP is 17.93%.The occurrence of CIP is closely related to the prolongation of PFS.Immunotherapy course>6 cycles is a favorable prognostic factor for PFS and OS of NSCLC patients.关键词
非小细胞肺癌/免疫检查点抑制剂/免疫相关不良反应/检查点抑制剂相关性肺炎/预后Key words
non-small cell lung cancer(NSCLC)/immune checkpoint inhibitor(ICI)/immune-related adverse event(irAE)/checkpoint inhibitor-associated pneumonia(CIP)/prognosis分类
医药卫生引用本文复制引用
陈翔,加冷·热哈提汗,顾国民,阿布地力·阿布都许库,莎毕娜·迪力夏提,杨喆,王海峰..非小细胞肺癌患者免疫检查点抑制剂相关性肺炎与免疫检查点抑制剂疗效相关性分析[J].中国肿瘤生物治疗杂志,2024,31(1):54-61,8.基金项目
新疆维吾尔自治区自然科学基金(No.2021D01C381) （No.2021D01C381）
